7 articles
The FDA's approval of the first oral GLP-1 for weight loss marks a massive shift in the obesity treatment landscape. We break down the 'Trojan Horse' science of SNAC technology and what it means for the future of medicine.
Google's AlphaFold 3 isn't just an update - it's a rewrite of biology. By moving from Evoformer to Diffusion, AI can now simulate not just proteins, but the 'interactions of all of life's molecules'. Here is the $100B impact on Pharma.
It’s not just another Ozempic. Eli Lilly’s Retatrutide uses a 'Triple G' mechanism to achieve 27% weight loss, rivaling bariatric surgery. Here is the science behind the new king of weight loss.
It sounds like Sci-Fi: dormant bacteria embedded in bridges that wake up when cracks appear, eat calcium lactate, and excrete limestone to heal the damage. Here is the biology of our future infrastructure.
The solution to Earth's hardest manufacturing problems is to leave Earth. We examine how zero-gravity factories are creating purer drugs and faster fiber optics.
RFK Jr. slashes mRNA funding while the CDC delays Hepatitis B vaccines. A cynical look at how disease outbreaks could fuel a volatile new era for biotech stocks.
A deep dive into the emerging field of GLP-1 receptor agonists for cats, exploring how drugs like Ozempic are being adapted to fight the feline obesity epidemic.